See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: July 21, 2005

Wounds Postherpetic Neuralgia Ovarian Cancer

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Wounds

This is a double-blind research study of an intravenous antibiotic to be used for seven days. You may qualify if you have major abscesses requiring surgical incision/drainage, or infected ulcers or wounds. You must be 18 years or older. Study related lab and medications provided at no cost. Research site located in Houston, Texas.

More Information

Please see http://www.centerwatch.com/patient/studies/cat205.html.

-----

Postherpetic Neuralgia

This study will assess the safety and efficacy of the investigational medication topical KDS-2000 (anandamine) in the treatment of pain associated with postherpetic neuralgia. This is a phase II study in which there are six visits over a period of seven weeks with six weeks of treatment. Compensation is $250.00 upon completion. Participants must be ages 18-80, and have pain persisting for greater than three months after the shingles rash has healed. Research site located in Palm Beach Gardens, Fla.

More Information

Please see http://www.centerwatch.com/patient/studies/cat638.html.

-----

Ovarian Cancer

The purpose of this research study is to determine if TLK286 in combination with carboplatin is more effective in shrinking tumors than liposomal doxorubicin when given to women with recurrent ovarian cancer. Qualified participants will be women 18 years or older with recurrent ovarian cancer after having already received platinum-based chemotherapy. Participants must have histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer and have recurrent ovarian cancer that can be measured by a CT or MRI scan. Research sites located throughout the United States.

More Information

Please see http://www.centerwatch.com/patient/studies/cat186.html.

-----

Copyright 2005 CenterWatch. All rights reserved.

Consumer News
undefined
undefinedundefined